Ergothioneine: Synthetic biology empowers new value for multi-domain B2B collaborations

In the wave of upgrading in the health, beauty, and pharmaceutical raw material industries, the "high efficiency, safety, and multifunctionality" of natural active ingredients have become the core keys for B-end enterprises to break through homogeneous competition. Ergothioneine (EGT, CAS No.: 497-30-3), as the only natural antioxidant that can penetrate the mitochondrial membrane, has rapidly risen from a niche raw material to a core hot spot spanning multiple fields such as health products, cosmetics, and pharmaceuticals, thanks to its multiple outstanding bioactivities including targeted antioxidation, neuroprotection, and anti-inflammation, as well as its unique property that the human body cannot synthesize on its own and must obtain from external sources. With the breakthrough development of synthetic biology technology, the challenge of large-scale production of Ergothioneine has been solved, significantly reducing costs and providing B-end enterprises with diversified product innovation and market breakthrough opportunities, making it one of the core categories with the greatest growth potential in the raw material industry in 2026.

Core Value Iteration: From "Extravagant Ingredients" to "Affordable Raw Materials," Synthetic Biology Reshapes the Industry Landscape

Ergothioneine's core competitiveness lies in its unique physiological protective function, but its industrialization process has long been limited by production technology. Initially, Ergothioneine relied primarily on fungal extraction or chemical synthesis. Fungal extraction yielded less than 0.1 g/L, was highly impurity-laden, and costly; chemical synthesis suffered from severe racemization and safety concerns, resulting in prices reaching tens of thousands of yuan per gram, limiting its application to high-end niche products and hindering large-scale B2B applications.

The rise of synthetic biology has fundamentally changed this landscape. Through gene editing, metabolic reprogramming, and directed evolution, researchers have successfully constructed highly efficient synthetic strains, overcoming the bottlenecks of natural extraction and chemical synthesis. A team from the Chinese Academy of Sciences integrated multiple microbial genes to construct an artificial synthetic pathway, introducing a betaine cycle module to reduce raw material costs, achieving a record-breaking yield of 7.2 g/L, up from 0.1 g/L globally. Leading domestic companies have used CRISPR to modify strains, shortening the fermentation cycle to 72 hours and achieving purity levels exceeding 99.9%, with some products reaching 99.99%, far surpassing international standards. Today, synthetic biology has reduced the production cost of Ergothioneine to one-tenth of that of traditional processes, and the price of food-grade raw materials has dropped from 1200 yuan/gram to 120 yuan/gram, completely breaking the label of "exorbitantly priced ingredient" and laying a solid foundation for large-scale application by B2B enterprises.

From an efficacy perspective, Ergothioneine's advantages are becoming increasingly apparent. Its efficiency in scavenging reactive oxygen species (ROS) is 6000 times that of Vitamin E. It can precisely target key tissues such as the brain, liver, and skin through the OCTN1 transporter protein, activating the Nrf2 pathway, upregulating endogenous antioxidant enzymes, and constructing a multi-level cellular protection system. Simultaneously, its metabolite hydrogen sulfide can regulate inflammatory responses and delay telomere shortening, and has been listed as a "longevity biomarker" by *Nature*. Its value in anti-aging, neuroprotection, and metabolic regulation has been confirmed by a large amount of scientific data, perfectly meeting the core demand of the B2B market for "natural, efficient, and safe" raw materials.

Multi-Sector Implementation: Precisely Adapting to B2B Needs and Unlocking Growth in Niche Markets

With the maturity of production technology and the reduction in costs, Ergothioneine has achieved large-scale implementation across multiple sectors, precisely adapting to the product innovation needs of B2B companies in health supplements, cosmetics, and pharmaceuticals. Downstream application scenarios continue to expand, and market potential continues to be released. According to industry data, the global Ergothioneine market size exceeded US$4.2 billion in 2025, with the Chinese market accounting for over 50% of the global share. The domestic market size reached RMB 1.43 billion in 2025 and is projected to increase to RMB 1.71 billion in 2026, maintaining a compound annual growth rate of over 19%. The raw material market size is already close to RMB 500 million.

Health Supplement Sector: Focusing on Anti-Aging and Precision Nutrition to Create Differentiated Products

The health supplement sector is currently Ergothioneine's most mature application scenario, accounting for 45% of downstream applications. With the increasing aging population and rising consumer health awareness, anti-aging, brain health, and immune regulation health supplements have become market hotspots. Ergothioneine, with its unique physiological functions, has become a core raw material choice in this sector. It can selectively eliminate senescent cells, delaying cellular aging. Simultaneously, it can penetrate the blood-brain barrier, promoting nerve cell repair and improving cognitive function, showing potential auxiliary improvement effects on neurodegenerative diseases such as Alzheimer's disease. Phase II clinical trials showed that daily supplementation with 150mg of ergothioneine improved memory scores by 18% in patients with mild cognitive impairment.

B2B health supplement companies can formulate it into various dosage forms such as capsules, tablets, and powders, or combine it with ingredients such as PQQ, nervonic acid, and glutathione to create compound supplements, focusing on anti-aging and brain health maintenance for middle-aged and elderly people, as well as anti-fatigue and immune-boosting needs for young and middle-aged people. Currently, well-known brands such as Swisse and By-Health have launched related products, and the demand for cross-border oral products is strong, becoming a new growth point in the health supplement market.

Cosmetics: Focusing on Cellular-Level Anti-Aging, Seizing the High-End Skincare Market

The cosmetics sector is the fastest-growing application scenario for Ergothioneine, accounting for 38% of downstream applications, and it is particularly well-suited to the high-end anti-aging skincare market. Driven by the consumer trends of "natural skincare" and "cell repair," Ergothioneine has become a new favorite among beauty companies due to its antioxidant, anti-inflammatory, and collagen-boosting effects. It protects the skin from damage caused by UV rays and free radicals, inhibits collagen degradation, and improves dullness, sagging, and fine lines. Clinical data shows that after 8 weeks of use, a 0.01%-0.1% concentration of Ergothioneine improves skin elasticity by 32.4%; it also alleviates skin inflammation, making it suitable for sensitive skin repair needs.

Even more noteworthy for B2B beauty companies is Ergothioneine's outstanding photostability; it does not easily decompose under different temperatures and pH levels, making it suitable for the production of various formulations such as serums, creams, masks, and pre-serums. Liposome encapsulation technology developed by leading domestic companies can increase the transdermal absorption rate of Ergothioneine by 40%, further enhancing product efficacy. In 2023, fewer than 50 skincare products containing Ergothioneine were registered; by 2025, this number had exceeded 180. Products like Proya's Ruby series use it as a key active ingredient, achieving sales exceeding 420 million yuan during the Double Eleven shopping festival, demonstrating its strong market acceptance.

Pharmaceuticals and Other Fields: Expanding into Innovative R&D and Exploring Potential Markets

Pharmaceuticals and other fields represent a significant growth driver for Ergothioneine, with downstream applications accounting for approximately 17%. In the pharmaceutical field, Ergothioneine's anti-inflammatory, neuroprotective, and antioxidant properties offer new directions for drug development. It is currently used in pharmaceutical intermediates, and some companies are collaborating with research institutions to conduct clinical trials in areas such as dry eye treatment and Alzheimer's disease intervention. A trial at Hefei First People's Hospital showed that postoperative eye drops containing Ergothioneine improved dry eye symptoms by 40%, with a potential pharmaceutical market size exceeding 20 billion yuan.

Furthermore, Ergothioneine is gradually expanding into areas such as pet health products and sports nutrition supplements. In pet health products, its antioxidant and anti-inflammatory effects can be used to create anti-aging and joint care products for pets; in the field of sports nutrition, it can be used to relieve muscle damage after exercise and accelerate recovery, meeting the needs of professional athletes and fitness enthusiasts, and providing more innovative directions for B-end enterprises.

Core Support for B2B Cooperation: Controllable Quality and Stable Supply, Helping Enterprises Reduce Costs and Increase Efficiency

For B2B enterprises, the stability of raw material quality, the reliability of supply, and cost-effectiveness are core factors determining product competitiveness and market positioning. Currently, domestic enterprises have achieved large-scale production of Ergothioneine, breaking the import monopoly. With its controllable quality, stable production capacity, and significant cost advantages, it has become the preferred partner for B2B enterprises.

Regarding quality control, high-quality suppliers have established a comprehensive quality control system. From strain screening and fermentation production to purification and testing, every step strictly adheres to GMP standards. High-precision detection methods such as HPLC and NMR are used to rigorously test product purity, impurity content, and microbial indicators. Multiple specifications of products are available, including cosmetic grade (≥99%), pharmaceutical grade (≥99.5%), and food grade (≥99.9%), with some products reaching a purity of 99.99%, far exceeding the industry average. Meanwhile, the product has obtained dual GRAS certification from the US FDA, European Novel Food certification, Japanese JACTA oral beauty clinical certification, and multiple international certifications including ISO, KOSHER, and HALAL. Complete testing reports such as COA, HNMR, and LC-MS are available to ensure product compliance and give B-end enterprises peace of mind.

Regarding supply assurance, leading domestic companies have built thousand-ton-level production lines equipped with large-scale fermentation tank clusters and maintain ample inventory, achieving a daily output of 3 tons. This can meet the full-scenario needs of B-end enterprises, from sample testing and small-batch production to large-volume procurement. Multiple packaging sizes are available, including 1kg, 5kg, and 25kg, with support for customization. The logistics system has been optimized to achieve rapid delivery nationwide, avoiding disruptions to production schedules due to raw material shortages. Furthermore, suppliers have established a capacity reserve mechanism, flexibly adjusting production capacity according to market demand changes to ensure stable market supply.

In terms of service support, high-quality suppliers, relying on professional R&D teams and application laboratories, provide B-end enterprises with one-stop customized services, including formula optimization, dosage form design, efficacy verification, and solubility assessment, helping enterprises shorten R&D cycles and quickly realize product innovation and market launch. They also provide free samples for enterprise testing, reducing R&D and procurement risks, and establish dedicated customer service teams to respond promptly to enterprise needs, achieving mutual benefit and win-win results.

Trend Forecast: Now is the Perfect Time for B2B Investment

With the continuous advancement of scientific research, the bioactivity and application scenarios of Ergothioneine will be further explored. Coupled with the increasing consumer demand for natural and healthy products, its market demand will maintain rapid growth. It is predicted that the global L-(+)-Ergothioneine market will reach US$407 million in 2032, with a compound annual growth rate of 26.5%, and the Chinese market will continue to lead global growth.

In the future, the Ergothioneine industry will exhibit three major development trends: First, accelerated technological integration, with the combination of synthetic biology and AI, will create "ultra-efficient strains," driving production levels to exceed 10g/L; second, continuous expansion of application scenarios, with new dosage forms such as oral nanocrystal preparations and transdermal microneedle patches constantly emerging, further improving product bioavailability; and third, ecological reconstruction and upgrading, with Ergothioneine becoming a platform molecule for "cell health management," driving the development of a trillion-dollar anti-aging industry chain.

For B2B companies, now is the golden window of opportunity to invest in Ergothioneine. Whether it's product upgrades for health supplement companies, high-end product strategies for cosmetics companies, or innovative R&D for pharmaceutical companies, Ergothioneine provides strong raw material support, helping companies break through the homogenization dilemma and seize market opportunities. Choosing a reliable, stable, and professional partner, leveraging their technological and cost advantages, will enable companies to quickly innovate and launch products, leading to breakthroughs and long-term development in Ergothioneine's industry landscape.